Changes in weight and glycemic control following obesity treatment with semaglutide or tirzepatide by discontinuation status
Obesity · 2025-09 · 33 (9) · 1657-1667
DOI: 10.1002/oby.24331 ↗Kurz gefasst
Fachartikel in der Zeitschrift Obesity, online erschienen am 10.06.2025. Verfasst von Hamlet Gasoyan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center for Value-Based Care Research, Departments of Internal Medicine and Geriatrics, Cleveland Clinic, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Obesity, Glycemic Control, Tirzepatide. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Cleveland Clinic Research Program Committees.
Abstract (Originalsprache)
Objective
The objective of this study was to characterize changes in body weight and glycated hemoglobin (in those with prediabetes at baseline) through 12 months by obesity pharmacotherapy discontinuation status.
Methods
This retrospective cohort study used electronic health record data from a large health system in Ohio and Florida to identify adults with overweight or obesity without type 2 diabetes who initiated injectable semaglutide or tirzepatide between 2021 and 2023. Treatment discontinuation was defined by a >90‐day gap between exhaustion of previous supply and next dispense or end of study follow‐up (December 2024) and was classified into early discontinuation (i.e., within 3 months of index date) and late discontinuation (i.e., within 3–12 months).
Results
We identified 7881 patients; 6109 received semaglutide, and 1772 received tirzepatide. A total of 80.8% had low maintenance dosages. Mean (SD) percentage weight reduction at 1 year was 8.7% (9.6%); and it was 3.6% (8.1%) with early discontinuation, 6.8% (9.1%) with late discontinuation, and 11.9% (9.2%) with non‐discontinuation ( p < 0.001). The mean (SD) absolute reduction in percent glycated hemoglobin at 1 year was 0.1 (0.4) with early discontinuation, 0.2 (0.4) with late discontinuation, and 0.4 (0.4) with non‐discontinuation ( p < 0.001).
Conclusions
The average weight reduction in this cohort was lower than that observed in the main phase 3 trials, likely because of higher rates of discontinuation and lower maintenance dosages.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center for Value-Based Care Research, Departments of Internal Medicine and Geriatrics, Cleveland Clinic, Cleveland, Ohio, USA.
- Department of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
- Department of Surgery, Bariatric and Metabolic Institute, Cleveland Clinic, Cleveland, Ohio, USA.
- Departments of Internal Medicine and Geriatrics, Cleveland Clinic, Cleveland, Ohio, USA.
- Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
- Endocrinology and Metabolism Institute, Cleveland Clinic, Cleveland, Ohio, USA.
ORCID-Profile: Hamlet Gasoyan, W Scott Butsch, Bartolome Burguera
Förderung
- Cleveland Clinic Research Program Committees
Zitieren
APA
Gasoyan, H., Butsch, W. S., Schulte, R., Casacchia, N. J., Le, P., Boyer, C. B., Griebeler, M. L., Burguera, B., & Rothberg, M. B. (2025). Changes in weight and glycemic control following obesity treatment with semaglutide or tirzepatide by discontinuation status. Obesity, 33(9), 1657-1667. https://doi.org/10.1002/oby.24331
Vancouver
Gasoyan H, Butsch WS, Schulte R, Casacchia NJ, Le P, Boyer CB, et al. Changes in weight and glycemic control following obesity treatment with semaglutide or tirzepatide by discontinuation status. Obesity. 2025;33(9):1657-1667. doi:10.1002/oby.24331
BibTeX
@article{Gasoyan2025,
author = {Gasoyan, Hamlet and Butsch, W Scott and Schulte, Rebecca and Casacchia, Nicholas J and Le, Phuc and Boyer, Christopher B and Griebeler, Marcio L and Burguera, Bartolome and Rothberg, Michael B},
title = {Changes in weight and glycemic control following obesity treatment with semaglutide or tirzepatide by discontinuation status},
journal = {Obesity},
year = {2025},
volume = {33},
number = {9},
pages = {1657--1667},
doi = {10.1002/oby.24331}
}
EUVIMED